These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
42. Real-world routine diagnostic molecular analysis for TP53 mutational status is recommended over p53 immunohistochemistry in B-cell lymphomas. de Haan LM; de Groen RAL; de Groot FA; Noordenbos T; van Wezel T; van Eijk R; Ruano D; Diepstra A; Koens L; Nicolae-Cristea A; Hartog WCED; Terpstra V; Ahsmann E; Dekker TJA; Sijs-Szabo A; Veelken H; Cleven AHG; Jansen PM; Vermaat JSP Virchows Arch; 2024 Oct; 485(4):643-654. PubMed ID: 37851120 [TBL] [Abstract][Full Text] [Related]
43. Comparative analysis of EZH2, p16 and p53 expression in uterine carcinosarcomas. Makk E; Bohonyi N; Oszter A; Éles K; Tornóczky T; Tóth A; Kálmán E; Kovács K Pathol Oncol Res; 2023; 29():1611547. PubMed ID: 38146588 [No Abstract] [Full Text] [Related]
44. A key role for EZH2 in epigenetic silencing of HOX genes in mantle cell lymphoma. Kanduri M; Sander B; Ntoufa S; Papakonstantinou N; Sutton LA; Stamatopoulos K; Kanduri C; Rosenquist R Epigenetics; 2013 Dec; 8(12):1280-8. PubMed ID: 24107828 [TBL] [Abstract][Full Text] [Related]
45. The Polycomb group protein EZH2 is upregulated in proliferating, cultured human mantle cell lymphoma. Visser HP; Gunster MJ; Kluin-Nelemans HC; Manders EM; Raaphorst FM; Meijer CJ; Willemze R; Otte AP Br J Haematol; 2001 Mar; 112(4):950-8. PubMed ID: 11298590 [TBL] [Abstract][Full Text] [Related]
46. Expression of enhancer of zeste homologue 2 is significantly associated with increased tumor cell proliferation and is a marker of aggressive breast cancer. Collett K; Eide GE; Arnes J; Stefansson IM; Eide J; Braaten A; Aas T; Otte AP; Akslen LA Clin Cancer Res; 2006 Feb; 12(4):1168-74. PubMed ID: 16489070 [TBL] [Abstract][Full Text] [Related]
47. p53 is associated with high-risk and pinpoints TP53 missense mutations in mantle cell lymphoma. Rodrigues JM; Hassan M; Freiburghaus C; Eskelund CW; Geisler C; Räty R; Kolstad A; Sundström C; Glimelius I; Grønbaek K; Kwiecinska A; Porwit A; Jerkeman M; Ek S Br J Haematol; 2020 Dec; 191(5):796-805. PubMed ID: 32748433 [TBL] [Abstract][Full Text] [Related]
48. Landscape of somatic mutations and clonal evolution in mantle cell lymphoma. Beà S; Valdés-Mas R; Navarro A; Salaverria I; Martín-Garcia D; Jares P; Giné E; Pinyol M; Royo C; Nadeu F; Conde L; Juan M; Clot G; Vizán P; Di Croce L; Puente DA; López-Guerra M; Moros A; Roue G; Aymerich M; Villamor N; Colomo L; Martínez A; Valera A; Martín-Subero JI; Amador V; Hernández L; Rozman M; Enjuanes A; Forcada P; Muntañola A; Hartmann EM; Calasanz MJ; Rosenwald A; Ott G; Hernández-Rivas JM; Klapper W; Siebert R; Wiestner A; Wilson WH; Colomer D; López-Guillermo A; López-Otín C; Puente XS; Campo E Proc Natl Acad Sci U S A; 2013 Nov; 110(45):18250-5. PubMed ID: 24145436 [TBL] [Abstract][Full Text] [Related]
50. Efficacy of venetoclax in high risk relapsed mantle cell lymphoma (MCL) - outcomes and mutation profile from venetoclax resistant MCL patients. Zhao S; Kanagal-Shamanna R; Navsaria L; Ok CY; Zhang S; Nomie K; Han G; Hao D; Hill HA; Jiang C; Yao Y; Nastoupil L; Westin J; Fayad L; Nair R; Steiner R; Ahmed S; Samaniego F; Iyer SP; Oriabure O; Chen W; Song X; Zhang J; Badillo M; Moghrabi O; Aranda J; Tang G; Yin CC; Patel K; Medeiros LJ; Li S; Vega F; Thirumurthi S; Xu G; Neelapu S; Flowers CR; Romaguera J; Fowler N; Wang L; Wang ML; Jain P Am J Hematol; 2020 Jun; 95(6):623-629. PubMed ID: 32239765 [TBL] [Abstract][Full Text] [Related]
51. MYC overexpression correlates with MYC amplification or translocation, and is associated with poor prognosis in mantle cell lymphoma. Choe JY; Yun JY; Na HY; Huh J; Shin SJ; Kim HJ; Paik JH; Kim YA; Nam SJ; Jeon YK; Park G; Kim JE Histopathology; 2016 Feb; 68(3):442-9. PubMed ID: 26100211 [TBL] [Abstract][Full Text] [Related]
52. Blastoid and Pleomorphic Mantle Cell Lymphoma Demonstrate Distinct Clinicopathologic and Genetic Features. Khanlari M; Mo H; Kim DH; Sakhdari A; Young KH; Jain P; Wang M; Li S; Kanagal-Shamanna R; Miranda RN; Vega F; Medeiros LJ; Ok CY Am J Surg Pathol; 2023 Aug; 47(8):849-858. PubMed ID: 37288826 [TBL] [Abstract][Full Text] [Related]
53. TP53 genomic status regulates sensitivity of gastric cancer cells to the histone methylation inhibitor 3-deazaneplanocin A (DZNep). Cheng LL; Itahana Y; Lei ZD; Chia NY; Wu Y; Yu Y; Zhang SL; Thike AA; Pandey A; Rozen S; Voorhoeve PM; Yu Q; Tan PH; Bay BH; Itahana K; Tan P Clin Cancer Res; 2012 Aug; 18(15):4201-12. PubMed ID: 22675170 [TBL] [Abstract][Full Text] [Related]
54. Enhancer of zeste homolog 2 expression is associated with tumor cell proliferation and metastasis in gastric cancer. Choi JH; Song YS; Yoon JS; Song KW; Lee YY APMIS; 2010 Mar; 118(3):196-202. PubMed ID: 20132185 [TBL] [Abstract][Full Text] [Related]
55. Real-world Comparison of P53 Immunohistochemistry and TP53 Mutation Analysis Using Next-generation Sequencing. Lee H; Cho YA; Kim DG; Son JY; Cho EY Anticancer Res; 2024 Sep; 44(9):3983-3994. PubMed ID: 39197898 [TBL] [Abstract][Full Text] [Related]
56. EZH2-mediated repression of GSK-3β and TP53 promotes Wnt/β-catenin signaling-dependent cell expansion in cervical carcinoma. Chen Q; Zheng PS; Yang WT Oncotarget; 2016 Jun; 7(24):36115-36129. PubMed ID: 27092879 [TBL] [Abstract][Full Text] [Related]